Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma

Hodgson, David C.; Gilbert, Ethel S.; Dores, Graça M.; Schonfeld, Sara J.; Lynch, Charles F.; Storm, Hans H.; Hall, Per; Langmark, Frøydis; Pukkala, Eero; Andersson, Michael; Kaijser, Magnus; Joensuu, Heikki; Fosså, Sophie D.; Travis, Lois B.

doi:10.1200/jco.2006.09.0936

Cited by 319 publications

(277 citation statements)

References 31 publications

(6 reference statements)

Supporting

Mentioning

262

Contrasting

Unclassified

Order By: Relevance

“…4,7,[11][12][13][14] A protective effect of breastfeeding on the risk of premenopausal breast cancer has been observed in several studies, although not in all analyses. [31][32][33][34][35][36][37] Although the small size of this cohort prohibits analysis of the possibility that lactation might be protective, further studies in larger survivor cohorts may be indicated.…”

Section: Discussionmentioning

confidence: 99%

Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy

McCullough

Najita

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Female survivors of therapeutic chest radiation often question whether they will have difficulty with breast feeding, given their prior exposure to breast radiation. In the current study, the rates of successful breastfeeding in long-term survivors who received chest radiotherapy (CXRT) as a treatment for Hodgkin lymphoma (HL) were examined. METHODS: A survey study of survivors of HL who were treated at the Joint Center for Radiation Therapy in Boston from 1969 through 1996 was performed. Patients were queried about childbearing and breastfeeding. The authors analyzed self-reported breastfeeding success in women who reported live births after CXRT and compared them with a sibling control group. RESULTS: Overall, 83 female survivors of HL who were treated with CXRT reported at least 1 birth after treatment. There were a total of 141 post-HL pregnancies resulting in births. In these women, the median age at the time of the HL diagnosis was 23 years (range, 14-40 years) and the median radiation dose was 41 grays (Gy) (range, 27-46 Gy). For survivors, 57 of the 94 (61%) breastfeeding attempts were successful, whereas within the control group, 74 of the 94 (79%) attempts were successful (P ¼.044). Accounting for maternal age at first birth and birth era, multivariable analysis suggested that HL survivors treated with CXRT may be less likely to breastfeed successfully than their siblings (odds ratio, 0.42; 95% confidence interval, 0.2-1.0 [P ¼.06]). CONCLUSIONS: The majority of female HL survivors who were treated with CXRT report being able to breastfeed successfully. However, the results of the current study indicate a trend toward less successful breastfeeding in survivors as a previously unreported late effect of radiation. Cancer 2010;116:4866-71.

show abstract

Section: Discussionmentioning

confidence: 99%

Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy

McCullough

Najita

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…8,9 Late effects, especially SPM and cardiovascular events, are well-known after first-line treatment of HL. [10][11][12][13][14][15][16] In contrast, only a few retrospective studies have addressed long-term effects after ASCT for relapsed or refractory HL. 17,18 Thus, long-term prospective data are lacking for first-relapsed or refractory HL treated with ASCT.…”

Section: A B D Cmentioning

confidence: 99%

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group

et al. 2015

View full text Add to dashboard Cite

“…[21] For instance, a risk model approximated that those diagnosed at the age of 30 with HL will have a 30 year cumulative risk of second primary malignancy for men and women at 18% and 26%, respectively, compared to age-matched risks of 7% and 9%. [22,23] The latency of the various second malignancies seen following therapy for HL varies by histology. Risk for myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) peak at three to five years after therapy and return to population baseline, or at most remain minimally elevated, by 10 years after.…”

Section: Second Primary Malignancymentioning

confidence: 99%